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Abstract
Background More than 90 % of exercise-related cardiac ar-
rests occur in men, predominantly those aged 45 years and
older with coronary artery disease (CAD) as the main cause.
The current sports medical evaluation (SME) of middle-aged
recreational athletes consists of a medical history, physical
examination, and resting and exercise electrocardiography.
Coronary CT (CCT) provides a minimally invasive low radi-
ation dose opportunity to image the coronary arteries. We
present the study protocol of the Measuring Athlete’s Risk
of Cardiovascular events (MARC) study. MARC aims to
assess the additional value of CCT to a routine SME in
asymptomatic sportsmen ≥45 years without known CAD.
Design MARC is a prospective study of 300 asymptomatic
sportsmen ≥45 years who will undergo CCT if the SME does
not reveal any cardiac abnormalities. The prevalence and
determinants of CAD (coronary artery calcium score ≥100
Agatston Units (AU) or ≥50 % luminal stenosis) will be
reported. The number needed to screen to prevent the occur-
rence of one cardiovascular event in the next 5 years, condi-
tional to adequate treatment, will be estimated.
Discussion We aim to determine the prevalence and severity
of CAD and the additional value of CCT in asymptomatic
middle-aged (≥45 years) sportsmen whose routine SME re-
vealed no cardiac abnormalities.
Keywords Athletes . Coronary artery disease . Risk .
Coronary artery calcium score .Multidetector computed
tomography
Background
Screening athletes to prevent cardiovascular events
Sudden cardiac death is often the first manifestation of coro-
nary artery disease (CAD), and is responsible for ≈50% of the
mortality of cardiovascular disease in developed countries [1].
Regular physical exercise is recommended to reduce cardio-
vascular morbidity and mortality and is gaining increased
popularity, especially in middle-aged and older persons [2].
Yet, exercise transiently increases the risk of cardiovascular
events, particularly in those with unknown cardiac disease.
More than 90 % of acute exercise-related cardiac events occur
in men, predominantly those aged 45 years and over [3].
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While sudden cardiac death in younger athletes (35 years or
younger) is mainly caused by cardiomyopathies, electrical
heart disease and coronary anomalies, in older athletes it is
predominantly caused by CAD (80 %) [4].
A recent paper on cardiac arrest during long distance
running implicated a causal role for demand ischaemia in
athletes with (unknown) CAD [2]. Absence of coronary
plaque rupture in these persons was surprising because prior
data [5] and expert consensus documents [4] have suggested
that exercise-induced acute coronary events result from ath-
erosclerotic plaque disruption and coronary thrombosis. It
follows that early identification of CAD should be an impor-
tant goal in the pre-participation evaluation of middle-aged
persons.
Despite the rare occurrence of cardiac events in young
athletes (<2 per 100,000 athletes per year) the study group
of Sport Cardiology of the European Society of Cardiology
(ESC) recommends mandatory pre-participation screening
(based on medical history, physical examination and a resting
electrocardiogram (ECG)) of athletes aged 35 years or youn-
ger [6]. Directing screening efforts at the rapidly growing
group of older athletes who have a 10-fold higher risk of
exercise-related cardiac arrests [3]—mainly attributable to
CAD—should be considered as well [7].
The 2011 ESC position paper on cardiovascular evaluation
of middle-aged/senior individuals engaged in leisure time
sports activities advocates the use of maximal exercise testing.
This is now frequently performed in the course of a sports
medical examination (SME), in addition to medical history,
physical examination, and the resting ECG [8].
Cardiovascular event risk: exercise testing and cardiac
imaging to detect coronary artery disease
Traditionally, risk scores such as the ESC Systematic COro-
nary Risk Evaluation (SCORE) are used to estimate cardio-
vascular event risk in asymptomatic persons, aiming to divide
them into low, intermediate and high risk categories. The
SCORE risk categories correspond to 0–4 %, 5–9 % and
10 % or higher 10-year cardiovascular mortality risk [9].
Cardiovascular risk scores have not specifically been devel-
oped for persons who are physically active. As exercise
favourably influences cardiovascular risk factors, e.g. by re-
ducing weight and blood pressure and improving the lipid
profile, traditional cardiovascular risk scores may underesti-
mate CV risk in persons who exercise regularly [10]. It has
also been suggested that regular, intense physical exercise
(e.g. multiple marathon running) in itself may be harmful to
the heart by causing myocardial fibrosis [11] and by contrib-
uting to coronary artery plaque formation with cardiovascular
events occurring at an alarmingly high rate (21 % 10-year
event rate) in a group of 108 recreational German marathon
runners aged 50 years or older [10]. Cardiovascular events
exclusively occurred in those with a coronary calcium score
(CACS) higher than 100 Agatston units (AU).
Adding maximal exercise testing to the cardiovascular
evaluation of middle-aged/senior athletes, as advocated by
the ESC, may be useful to identify some persons at high risk,
by detecting a physiologically significant coronary artery
stenosis [12]. Several studies have indicated that asymptom-
atic men with an abnormal exercise test received the greatest
benefits of interventions to reduce risk factors [13]. Notwith-
standing the low predictive value (high false-negative rate) for
CAD of both resting and exercise electrocardiography in
asymptomatic individuals, exercise testing is still frequently
performed in the course of a sports medical check-up [14].
This is partly attributable to the fact that the results of exercise
testing will also provide information on cardiorespiratory
fitness relevant to recommendations for subsequent training
programs.
Coronary CT (CCT) can be of added value by providing a
minimally invasive opportunity to image the coronary arteries
for coronary artery calcium (CAC), atherosclerotic burden and
coronary stenosis [15].
Non-contrast CCT for the assessment of CAC provides a
non-invasive direct measure of burden of coronary atheroscle-
rosis and is an independent predictor of cardiovascular events
[16]. The CACS is the most powerful cardiac risk prognosti-
cator in the asymptomatic population, with consistent superi-
ority to all risk factor-based scores [17]. Absence of CAC is
associated with a very low risk of future cardiovascular events
in asymptomatic as well as symptomatic individuals [18]. The
amount of CAC, however, relates poorly to the degree of
luminal narrowing of the coronary arteries and a low CACS
does not exclude CAD [19, 20]. The ‘Agatston Score’ remains
the most commonly used measure to quantify CAC because
most previous large-scale trials and cross-sectional studies
used this method, so that large reference datasets exist (e.g.
http://www.mesa-nhlbi.org/Calcium) [21]. Coronary artery
calcification is age, gender, and race dependent. Agatston
scores are often classified into five groups according to
severity as listed in Table 1 [22]. A score <100 Agatston
Table 1 Classification of coronary calcium score







Classification of coronary calcium absolute content evaluated by cardiac
CT and quantified by Agatston units
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units (AU) is ranked as low risk, scores between 100
and 400 AU as intermediate (moderate) and above
400 AU as severe risk of future atherosclerotic cardio-
vascular events [22]. CACS is increasingly used as a
tool to expand risk stratification in asymptomatic per-
sons with an intermediate risk of cardiovascular events
[23]. The low number needed to screen in the general
population to identify an individual with moderate or
severe CAC (8 and 20 respectively) seems to provide a
justification for extending CAC testing to lower risk
individuals [16] as CAC is also associated with risk of
cardiovascular events among individuals with few or no
risk factors. The 5-year number needed to treat to pre-
vent a cardiovascular event in persons with a CACS
≥100 AU is low (19) [24] compared with the 5-year
number needed to treat to prevent a cardiovascular
event in patients with mild to moderate (140–
160 mmHg) hypertension (122 to 135) [25].
Coronary CT angiography
Low-dose coronary CT angiography (CCTA) can visu-
alise, qualify (calcified, non-calcified, mixed plaques),
and quantify (total atherosclerotic burden, degree of
luminal stenosis) CAD and is increasingly used to rule
out CAD in persons presenting with chest pain. The
diagnostic accuracy of CCTA is high, regardless of risk
profile [26]. In the near future CT fractional flow re-
serve is likely to provide information on the functional
significance of coronary artery stenosis [27]. The vul-
nerable plaque paradigm states that plaque composition
is a better predictor of acute coronary events than ste-
nosis grade [28]. As athletes normally have a lower
heart rate and BMI, they are suitable candidates for
low radiation dose (2–3 millisievert—mSv) CCTA to
determine the presence and extent of CAD. This dose
corresponds to the yearly background radiation each
person receives in Europe [29]. Furthermore, a recent
position paper that analysed acute and long-term com-
posite risks related to cardiovascular imaging showed
that life-time risk of imaging procedures for fatal events
is small compared with the general risk of fatal cardiac
events by CAD in both asymptomatic and symptomatic
populations [30].
Aim
The aim of the Measuring Athlete’s Risk of Cardiovas-
cular events (MARC) study is to determine the preva-
lence and severity of CAD and the additional value of
CCT in asymptomatic middle-aged (≥45 years) sports-
men whose rout ine SME revealed no cardiac
abnormalities.
Methods/design
MARC is a prospective, cross-sectional study. Asymptomatic
sportsmen aged 45 years and older, without known cardiovas-
cular disease, engaged in competitive or recreational leisure
sports or contemplating initiating regular exercise and with a
normal SME (including resting and exercise electrocardiogra-
phy) will be invited to undergo additional CCT. Baseline
characteristics, including demography, cardiovascular risk
factors, sports history, medical history and medication use,
will be obtained. The results of the CCT, combined with the
conventional cardiovascular risk profile, will be used to pro-
vide the participants with a tailored cardiovascular advice,
based on the prevailing cardiovascular disease prevention
and sports medicine guidelines [9, 31].
Based on the number of participants (n=108) in the only
cardiac CT study of asymptomatic athletes to date and the
yearly number of persons (n=300–350) performing a SME at
an average Dutch sports medical department who would
qualify for participation in MARC, we aim to include 300
asymptomatic participants to obtain estimates of the preva-
lence of coronary artery disease with reasonable confidence
intervals and to determine the added value of CCT (CACS and
CCTA) in the prevention of cardiovascular events. Given the
10- to 30-fold higher incidence of exercise-related cardiac
arrests in men than in women we choose to enrol men only
[32].
Coronary CT imaging
Coronary CT is performed using a 256-slice CT scanner
(Philips Healthcare, Best, the Netherlands). A non-contrast
coronary CT is acquired first to calculate the CACS (scan
parameters 120 kV, 60 mAs). Participants with a heart rate
>65 beats/min will receive 5 to 20 mg metoprolol (Selokeen
AstraZeneca, Zoetermeer, the Netherlands) intravenously be-
fore CCTA. All participants receive two puffs of sublingual
nitroglycerine spray just before the CCTA. CCTA scan pa-
rameters will be as follows: 120 kV; 210 mAs; 90–120 ml
(depending on weight) non-ionic contrast material
(Iopromide, 300 mg I/ml; Ultravist, Bayer Healthcare, Berlin,
Germany) will be injected at a speed of 6–6.7 ml/s followed
by 30–40 ml saline injected at the same speed. The CCTA is
acquired with prospective ECG triggering at a mid-diastolic
phase (78 %).
To determine the amount and distribution of soft and mixed
coronary artery plaques CCTAwill be done regardless of the
CACS. In clinical practice CCTA is often withheld in patients
with a CACS >400 AU because blooming artefacts might
hinder the evaluation of coronary artery stenosis [33].
The total CCT radiation dose to which participants will be
exposed is anticipated to be 3 mSv on average [34]. Partici-
pants receive extensive written and oral information prior to
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examination. If renal function is unknown, the creatinine is
measured before the scan. Participants with renal dysfunction
(estimated glomerular filtration rate <60 ml/min/1.73 m2) will
be excluded from the study. Blood pressure and heart rate are
available from the SME and will also be measured before the
CT scan.
Image analysis
CTscans are sent to a workstation (IntelliSpace Portal, Philips
Healthcare) for processing by experienced technicians. All CT
scans are analysed by one of two experienced observers.
Assessment of coronary artery calcium score
CACS is measured on the non-contrast CT with the Agatston
scoring method [35]. Coronary artery calcium is measurable
above a density of >130 Hounsfield units (HU) in a coronary
artery. Total CACS is calculated by the sum of all lesions in all
four coronary arteries and their side branches. The total
Agatston score will be compared with the MESA database
[21].
Assessment of coronary CT angiography
Specialised technicians use semi-automated vessel analysis to
make multiple curved multiplanar reconstructions (MPR) of
all coronary arteries on the CCTA data. The radiologist views
these MPR reconstructions as well as the thin-slice CCTA
source images with interactive maximum intensity projection
and MPR viewing possibilities in all planes. Image quality,
plaque characteristics and coronary lumen stenosis will be
analysed on a 16-segment basis according to the modified
American Heart Association classification [36].
Plaque composition will be evaluated in a qualitative man-
ner as calcified (more than 50 % of the plaque area calcified),
mixed (plaques with <50 % calcium) and non-calcified
(plaques without calcium) [37].
Total atherosclerotic plaque burden will be measured with
both the segmental involvement score (SIS) and the segment
stenosis score (SSS) based on the 16-segment coronary artery
model. [38] Luminal stenosis will be graded as absent, mini-
mal (1–24 %), mild (25–49 %), moderate (50–69 %), and
severe (≥70 %) [39] narrowing on the basis of diameter
measurements comparing the diameters of the maximal ste-
nosis to a reference diameter proximal and distal to the ste-
notic area. If severe calcifications are present and quantifica-
tion of stenosis is difficult, the radiologist will refrain from
stenosis quantification and score the segments involved as
‘calcified, stenosis unclear’.
Outcome and consensus meetings
The primary outcome is the presence of relevant CAD that
will be defined as one or more of the following on CT: a
CACS ≥100 AU or luminal stenosis ≥50 %. Participants with
a CACS ≥100 AU will be reclassified to high risk [24].
Consensus meetings with a panel of at least two (sports)
cardiologists and one radiologist will be held regularly to
advise on the management of participants found to have
relevant CAD. As a general rule participants with a CACS
between 100 and 400 AU without obstructive CAD will be
recommended to initiate treatment with statins, in addition to
lifestyle advice [40]. Participants with a CACS ≥400 AU or
coronary stenosis ≥50 % will be given the opportunity to
consult a cardiologist for further cardiovascular workup.
Statistical analysis
Analysis of the (baseline) results from this study will be
descriptive (presence and extent of CAD). Descriptive statis-
tics will be presented as means and standard deviations for
continuous variables, and frequencies and percentages for
categorical data. The two-tailed independent t-test will be used
for comparison between groups (e.g. those with and without
coronary artery disease) and analysis of variance will be used
to compare means of more than two groups. The chi-square
test will be used to examine the association between categor-
ical variables. Linear regression and multivariate regression
analysis will be used to study the relation between character-
istics of the participants and CCT determined CAD.
The number needed to screen to prevent one cardiovascular
event (defined as coronary heart disease events -myocardial
infarction, death from coronary heart disease, definite angina,
probable angina resulting in revascularisation or resuscitated
cardiac arrest-, stroke, or other atherosclerotic death or other
cardiovascular death) within 5 years will be computed based
on the reciprocal of the prevalence of CAD (CACS ≥100 AU
and / or luminal narrowing ≥50 %) (multiplied by 100) mul-
tiplied by the number needed to treat to prevent one cardio-
vascular event [24].
Statistical analyses will be performed with SPSS version
22.0 (SPSS Inc., Chicago, Illinois, USA). A p-value of less
than 0.05 will be regarded as statistically significant.
Ethical considerations
This study has been approved by the regional Medical Ethics
Committee (VCMO, Nieuwegein, the Netherlands) and sub-
sequently approved by the local ethics board committee of the
University Medical Center Utrecht, the Netherlands. The
study is being conducted according to the principles of the
Declaration of Helsinki and in accordance with the Dutch
Medical Research Involving Human Subjects Act.
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Participants are only included in the MARC study after writ-
ten informed consent is obtained.
Discussion
The MARC study will assess the additional value of low-dose
coronary CCT to determine the prevalence and severity of
CAD in 300 asymptomatic middle-aged (≥45 years) sports-
men, in whom an SME found no cardiac abnormalities. Par-
ticipants of the MARC study should reflect the fast growing
group of men aged 45 years or older who decide to undergo a
SME that includes exercise testing. As such, we anticipate to
include both competitive and recreational athletes. The ma-
jority of them are likely to be engaged in high dynamic high
static sports (e.g. race cycling) and high dynamic low static
sports (e.g. long distance runners). The number needed to
screen with CCT to prevent the occurrence of one cardiovas-
cular event in the next 5 years will be estimated.
Sudden cardiac death is the most devastating sport-related
event. Although regular exercise reduces the risk of cardio-
vascular disease, the risk of an acute cardiac event is transient-
ly increased during and immediately after vigorous exercise
[4] Sports-related cardiac events occur mainly in those with
unknown cardiac disease, which prompts many sportsmen to
undergo a SMEwith exercise testing. TheMARC study offers
the most comprehensive cardiovascular evaluation of middle-
aged sportsmen to date, by adding CCT (both CACS and
CCTA) to the routine SME.
CT scanning is generally considered safe but, apart from
radiation exposure (discussed in the Background section:
CCTA), the following considerations should be taken into
account when evaluating asymptomatic persons with CCT.
Potential risks of CCTA include adverse reaction to the con-
trast media (nausea, skin hives in 1 to 3 % of participants, fatal
adverse reactions in 1 in 100,000 participants) and contrast
media-induced renal insufficiency (contrast nephropathy).
The occurrence of contrast nephropathy is directly related to
renal function; by selecting participants with a GFR higher
than 60 ml/min contrast nephropathy is unlikely to occur [41].
The result of the CCT may lead to additional diagnostic
tests with extra costs and risks not covered by this study.
However, the Eisner study demonstrated that CAC scanning
compared with no scanning in asymptomatic volunteers can
improve cardiac management without incurring a significant
increase in downstreammedical costs [42]. Incidental findings
will be reported to the participant and his general practitioner.
Pulmonary nodules are likely to be common incidental find-
ings in our study and will be managed according to the
Fleischner criteria [43].
The results of the MARC study will give insight into the
added value of CCT in the cardiovascular evaluation of
asymptomatic sportsmen aged 45 years and older who have
undergone a routine SME. We anticipate that our study will
provide guidance in the debate on the optimal pre-participation
evaluation of the rapidly growing group of older sportsmen in
whom CAD is the main cause of cardiovascular events.
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